OraSure Technologies (OraSure Technologies) ROCE % : 6.71% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OraSure Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was 6.71%.

OraSure Technologies ROCE % Historical Data

The historical data trend for OraSure Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies ROCE % Chart

OraSure Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

2.58

-1.73

-2.91

-1.37

10.61

OraSure Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															15.74	26.07	-6.16	16.53	6.71

OraSure Technologies ROCE % Calculation

OraSure Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	43.414	/	( ( (444.18 - 69.063)	+	(482.845 - 39.536) )	/ 2 )
	=	43.414	/	( (375.117	+	443.309)	/ 2 )
	=	43.414	/	409.213
	=	10.61 %

OraSure Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	28.896	/	( ( (458.432 - 40.947)	+	(482.845 - 39.536) )	/ 2 )
	=	28.896	/	( ( 417.485	+	443.309 )	/ 2 )
	=	28.896	/	430.397
	=	6.71 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

OraSure Technologies (NAS:OSUR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OraSure Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OraSure Technologies (OraSure Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

EP3:Germany

Address

220 East First Street, Bethlehem, PA, USA, 18015

Website

https://www.orasure.com

OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.

Executives

Kathleen Gallagher Weber	officer: Chief Product Officer	220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller	officer: VP, Finance and Controller	220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath	officer: Chief Financial Officer	C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster	director	ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano	director	33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton	director, officer: President & CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason	officer: Interim CFO/SVP IR	1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs	director	C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin	director	21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora	director	64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer	officer: President of Diagnostics	1 CRESENT PLACE, SHORT HILLS NJ 07078